107 related articles for article (PubMed ID: 32413726)
21. Comparison of the seventh and eighth editions of the UICC/AJCC staging system for nasopharyngeal carcinoma: analysis of 1317 patients treated with intensity-modulated radiotherapy at two centers.
Yang XL; Wang Y; Liang SB; He SS; Chen DM; Chen HY; Lu LX; Chen Y
BMC Cancer; 2018 May; 18(1):606. PubMed ID: 29843648
[TBL] [Abstract][Full Text] [Related]
22. Survival without concurrent chemotherapy for locoregionally advanced nasopharyngeal carcinoma treated with induction chemotherapy plus intensity-modulated radiotherapy: Single-center experience from an endemic area.
Fangzheng W; Chuner J; Haiyan Q; Quanquan S; Zhimin Y; Tongxin L; Jiping L; Peng W; Kaiyuan S; Zhenfu F; Yangming J
Medicine (Baltimore); 2019 Dec; 98(51):e18484. PubMed ID: 31861031
[TBL] [Abstract][Full Text] [Related]
23. A retrospective study comparing the outcomes and toxicities of intensity-modulated radiotherapy versus two-dimensional conventional radiotherapy for the treatment of children and adolescent nasopharyngeal carcinoma.
Qiu WZ; Peng XS; Xia HQ; Huang PY; Guo X; Cao KJ
J Cancer Res Clin Oncol; 2017 Aug; 143(8):1563-1572. PubMed ID: 28342002
[TBL] [Abstract][Full Text] [Related]
24. Quality of life and survival outcome for patients with nasopharyngeal carcinoma treated by volumetric-modulated arc therapy versus intensity-modulated radiotherapy.
Huang TL; Tsai MH; Chuang HC; Chien CY; Lin YT; Tsai WL; Fang FM
Radiat Oncol; 2020 Apr; 15(1):84. PubMed ID: 32307024
[TBL] [Abstract][Full Text] [Related]
25. Minimally invasive surgery alone compared with intensity-modulated radiotherapy for primary stage I nasopharyngeal carcinoma.
Liu YP; Lv X; Zou X; Hua YJ; You R; Yang Q; Xia L; Guo SY; Hu W; Zhang MX; Chen SY; Lin M; Xie YL; Liu LZ; Sun R; Huang PY; Fan W; Guo X; Hong MH; Chen MY
Cancer Commun (Lond); 2019 Nov; 39(1):75. PubMed ID: 31730020
[TBL] [Abstract][Full Text] [Related]
26. Nasopharyngeal carcinoma treated with intensity-modulated radiotherapy: clinical outcomes and patterns of failure among subsets of 8th AJCC stage IVa.
Huang CL; Guo R; Li JY; Xu C; Mao YP; Tian L; Lin AH; Sun Y; Ma J; Tang LL
Eur Radiol; 2020 Feb; 30(2):816-822. PubMed ID: 31650266
[TBL] [Abstract][Full Text] [Related]
27. Effect of adaptive replanning in patients with locally advanced nasopharyngeal carcinoma treated by intensity-modulated radiotherapy: a propensity score matched analysis.
Luo Y; Qin Y; Lang J
Clin Transl Oncol; 2017 Apr; 19(4):470-476. PubMed ID: 27718153
[TBL] [Abstract][Full Text] [Related]
28. Long-term outcomes of intensity-modulated radiotherapy for 868 patients with nasopharyngeal carcinoma: an analysis of survival and treatment toxicities.
Sun X; Su S; Chen C; Han F; Zhao C; Xiao W; Deng X; Huang S; Lin C; Lu T
Radiother Oncol; 2014 Mar; 110(3):398-403. PubMed ID: 24231245
[TBL] [Abstract][Full Text] [Related]
29. Prognostic factors of 305 nasopharyngeal carcinoma patients treated with intensity-modulated radiotherapy.
Han L; Lin SJ; Pan JJ; Chen CB; Zhang Y; Zhang XC; Liao XY; Chen QS
Chin J Cancer; 2010 Feb; 29(2):145-50. PubMed ID: 20109341
[TBL] [Abstract][Full Text] [Related]
30. High-Dose Static and Dynamic Intensity-Modulated Radiotherapy Combined with Chemotherapy for Patients with Locally Advanced Nasopharyngeal Carcinoma Improves Survival and Reduces Brainstem Toxicity.
Sun PY; Chen YH; Feng XB; Yang CX; Wu F; Wang RS
Med Sci Monit; 2018 Dec; 24():8849-8859. PubMed ID: 30524119
[TBL] [Abstract][Full Text] [Related]
31. Significance of boost dose for T4 nasopharyngeal carcinoma with residual primary lesion after intensity-modulated radiotherapy.
Fei Z; Xu T; Qiu X; Li M; Chen T; Li L; Huang C; Chen C
J Cancer Res Clin Oncol; 2021 Jul; 147(7):2047-2055. PubMed ID: 33392660
[TBL] [Abstract][Full Text] [Related]
32. T4/N2 classification nasopharyngeal carcinoma benefit from concurrent chemotherapy in the era of intensity-modulated radiotherapy.
Xie R; Xia B; Zhang X; Hu W; Zhao R; Xie C; Wang J; Zhang N; Wu S
Oncotarget; 2016 Dec; 7(49):81918-81925. PubMed ID: 27636993
[TBL] [Abstract][Full Text] [Related]
33. Risk Assessment of Secondary Primary Malignancies in Nasopharyngeal Carcinoma: A Big-Data Intelligence Platform-Based Analysis of 6,377 Long-term Survivors from an Endemic Area Treated with Intensity-Modulated Radiation Therapy during 2003-2013.
Zhang LL; Li GH; Li YY; Qi ZY; Lin AH; Sun Y
Cancer Res Treat; 2019 Jul; 51(3):982-991. PubMed ID: 30309219
[TBL] [Abstract][Full Text] [Related]
34. Treatment outcomes after reduction of the target volume of intensity-modulated radiotherapy following induction chemotherapy in patients with locoregionally advanced nasopharyngeal carcinoma: A prospective, multi-center, randomized clinical trial.
Yang H; Chen X; Lin S; Rong J; Yang M; Wen Q; Shang C; He L; Ren P; Xu S; Zhang J; Liu Q; Pang H; Shi X; Fan J; Sun X; Ma D; Tan B; Zhang T; Zhang L; Hu D; Du X; Zhang Y; Wen S; Zhang X; Wu J
Radiother Oncol; 2018 Jan; 126(1):37-42. PubMed ID: 28864073
[TBL] [Abstract][Full Text] [Related]
35. Prognostic value of gross tumor regression and plasma Epstein Barr Virus DNA levels at the end of intensity-modulated radiation therapy in patients with nasopharyngeal carcinoma.
Liang SB; Zhang N; Chen DM; Yang XL; Chen BH; Zhao H; Lu RL; Chen Y; Fu LW
Radiother Oncol; 2019 Mar; 132():223-229. PubMed ID: 30366725
[TBL] [Abstract][Full Text] [Related]
36. Intensity-modulated radiotherapy prolongs the survival of patients with nasopharyngeal carcinoma compared with conventional two-dimensional radiotherapy: A 10-year experience with a large cohort and long follow-up.
Zhang MX; Li J; Shen GP; Zou X; Xu JJ; Jiang R; You R; Hua YJ; Sun Y; Ma J; Hong MH; Chen MY
Eur J Cancer; 2015 Nov; 51(17):2587-95. PubMed ID: 26318726
[TBL] [Abstract][Full Text] [Related]
37. Salvage treatment using carbon ion radiation in patients with locoregionally recurrent nasopharyngeal carcinoma: Initial results.
Hu J; Bao C; Gao J; Guan X; Hu W; Yang J; Hu C; Kong L; Lu JJ
Cancer; 2018 Jun; 124(11):2427-2437. PubMed ID: 29579324
[TBL] [Abstract][Full Text] [Related]
38. Long-Term Use of Nimotuzumab in Combination With Intensity-Modulated Radiotherapy and Chemotherapy in the Treatment of Locoregionally Advanced Nasopharyngeal Carcinoma: Experience of a Single Institution.
Fangzheng W; Chuner J; Zhiming Y; Tongxin L; Fengqin Y; Lei W; Bin L; Fujun H; Ming C; Weifeng Q; Zhenfu F
Oncol Res; 2018 Mar; 26(2):277-287. PubMed ID: 29046165
[TBL] [Abstract][Full Text] [Related]
39. [Analysis of follow-up results of chrono-chemotherapy or conventional chemotherapy combined with intensity modulated radiotherapy in locally advanced nasopharyngeal carcinoma].
Liu KQ; Jin F; Jiang H; Wu WL; Li YY; Long JH; Luo XL; Gong XY; Chen XX; Liu LN; Gan JY; Zhou JJ
Zhonghua Zhong Liu Za Zhi; 2020 Feb; 42(2):133-138. PubMed ID: 32135648
[No Abstract] [Full Text] [Related]
40. Clinical outcome for nasopharyngeal carcinoma with predominantly WHO II histology treated with intensity-modulated radiation therapy in non-endemic region of China.
Zhao LN; Zhou B; Shi M; Wang JH; Xiao F; Xu M; Luo SQ; Xue Y; Li JP; Tan LN
Oral Oncol; 2012 Sep; 48(9):864-9. PubMed ID: 22445296
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
